Go Unlimited with Magzter GOLD
Get unlimited access to 10,000+ magazines, newspapers and Premium stories for just
Try GOLD - Free
Making India A $100-bn Biomanufacturing Hub By 2024
Express Pharma
|February 16-29, 2020
Industry experts outline how Prime Minister Narendra Modi's dream of 'Make in India' for the biomanufacturing sector can be fulfilled in the stipulated time frame
As the year 2020 began, Prime minister Narendra Modi came up with good news for the biotechnology sector. Speaking at the inauguration of the 107th session of the Indian Science Congress at the University of Agricultural Sciences in Bengaluru last month, Modi said, “We aim to develop India as a world-class $100-billion biomanufacturing hubby 2024.”
“The growth story of India depends on its achievements in the science and technology sector. There is a need to revolutionize the landscape of Indian science, technology and innovation. My motto for the young scientists burgeoning in this country has been -innovate, patent, produce and prosper. These four steps will lead our country towards faster development. If we innovate, we will patent and that, in turn, will make our production smoother and when we take these products to the people of our country, they will prosper. Innovation for the people and by the people is the direction of our ‘New India’,” he added.
While the biotechnology sector is one of the key drivers for contributing to India's $5 trillion economy target by 2024, the Indian biotechnology sector is poised to grow exponentially over the next decade. Further, the country is among the top-12 destinations for biotechnology in the world, with approximately three per cent share in the global biotechnology industry.
The biotech sector can be broadly divided into five major segments — biopharma (which accounts for around 55 per cent of the revenue of the total sector), bio-agri (22 per cent of market share), services, bioindustrial and bioinformatics. According to Invest India, the National Investment Promotion and Facilitation Agency, the Indian biotechnology industry was valued at $51-billion in 2018 and is growing at almost 15 per cent year-on-year.
Potential that the biotechnology sector holds
This story is from the February 16-29, 2020 edition of Express Pharma.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Express Pharma
Express Pharma
NEEDLES, PENS AND PRESSURE THE GLP-1 CHALLENGE
As GLP-1 therapies transform diabetes and obesity care, demand for prefilled pens and injectors is soaring. Pharma-device collaborations, analytical innovation, and sustainable design will be key to tackle the growing device bottleneck
7 mins
November 2025
Express Pharma
Unified standards and smarter design are key to unlocking next-generation HVAC performance
Current HVAC design relies on a diverse, and sometimes confusing, array of guidelines issued by regulatory bodies such as WHO, EU GMP, ISO 14644, ISPE Baseline, and ASHRAE/ISHRAE.
2 mins
November 2025
Express Pharma
Kyasanur Forest Disease - How far is a regulatory approved vaccine?
Dr Priyabrata Pattnaik, Former Deputy MD, Indian Immunologicals, informs about the Kyasanur Forest Disease (KFD), a zoonotic viral hemorrhagic fever endemic to parts of India, particularly along the Western Ghats and discusses the current status of developing a regulatory-approved KFD vaccine in India
3 mins
November 2025
Express Pharma
India's biopharma industry charts the road from biosimilars to innovation
Express Pharma hosted the maiden Biopharma Leadership Conclave 2025 and brought together industry leaders to discuss how India can move from being the world's leading producer of generics and biosimilars to becoming a hub for innovative, affordable, and high-quality biologics and advanced therapies
4 mins
November 2025
Express Pharma
Digital technologies are quietly transforming HVAC into an intelligent compliance partner
Over the last decade, HVAC standards in pharmaceutical manufacturing have undergone a quiet revolution.
2 mins
November 2025
Express Pharma
Direct-to-Retail will increasingly complement traditional pharma distribution
Aqualab has crossed Rs 100 crore in just three years, what have been the key drivers behind this growth, and how does the brand plan to achieve the Rs 250 crore target by FY25-26?Aqualab's journey to Rs 100 crore within three years reflects the strength of a simple yet powerful principle, accessibility through proximity. Our growth has been anchored in three areas: a high-velocity retail network that prioritises last-mile availability, a well-diversified therapeutic portfolio spanning acute and chronic segments, and a strong focus on brand trust built through consistent product quality.
3 mins
November 2025
Express Pharma
Guaranteeing continuity of medicine supply through AI innovation
Hari Kiran Chereddi highlights how AI is transforming pharma supply chains to ensure uninterrupted medicine availability
2 mins
November 2025
Express Pharma
PROSOLV® 730: Directly compressible carrier for lipophilic ingredients
Nearly 90 % of molecules in the discovery pipeline and 40 % of drugs with market approval are poorly water soluble. Poor aqueous solubility can lead to low bioavailability resulting in insufficient plasma levels. Oil-based preparations of these APIs, as well as oily APIs in general, present challenges in terms of solid dosage form manufacturing. PROSOLV® 730 was designed to provide a solution to the formulation of BCS class II and IV APIs. It enables the formulation of lipidic APIs or API-loaded lipid systems by facilitating the adsorption of oil, creating a free-flowing, compactible system that can be further formulated. PROSOLV® 730 is a co-processed, high-functionality excipient comprising MCC SILICA COPOVIDONE
2 mins
November 2025
Express Pharma
Ensuring Clean Room Integrity with Prime Clean Reset High-Speed Doors: Minimizing Air Permeability and Leakages
High-speed doors for clean rooms are specialized industrial doors essential for maintaining controlled environments. These doors are engineered to be airtight, creating a reliable barrier between different areas of a facility. Their design ensures durability and minimal maintenance, reducing the frequency of repairs and replacements.
2 mins
November 2025
Express Pharma
Reimagining cold chain: How IoT secures every pharma mile
Swarup Bose, Co-founder and CEO, Celcius Logistics points out that as the demand for temperature-sensitive medicines surges, maintaining an unbroken cold chain has never been more critical. IoT is emerging as the game-changer that ensures every vial and vaccine arrives potent, safe, and on time
3 mins
November 2025
Translate
Change font size